City of Hope Leads AI-Powered Health Care Innovations and Launches Generative AI Tool to Save Lives and Enable Nationwide Best-in-Class Cancer Care
LOS ANGELES--(BUSINESS WIRE)--City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center named a Top 5 'Best Hospital' in the nation for cancer care by U.S. News & World Report, is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials and empower breakthrough research.
City of Hope is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials and empower breakthrough research.
Share
'With the rise of AI, health care systems like City of Hope are seizing the opportunity to transform physician workloads and fuel more focused, personalized patient care,' said Simon Nazarian, City of Hope chief digital and technology officer and system executive vice president.
Among City of Hope's most exciting health care innovations is a novel generative AI platform that leverages multiple commercial and open-source AI models. HopeLLM — powered by City of Hope's proprietary technology and data — removes the administrative burden of new patient onboarding, matches patients to clinical trials, enables generative AI responses personalized to individual patient records and extracts real-world data for research.
'By summarizing massive information in seconds, HopeLLM removes a barrier between the patient and the doctor. Instead of spending time finding information in the history of previous tests and treatments, doctors can spend time and effort in getting patients and caregivers to understand treatment options. Instead of the frustration of trying to find information, doctors are able to create more joy as they deliver patient care,' said Vijay Trisal, M.D., City of Hope system chief clinical officer and the Dr. Norman & Melinda Payson Professor in Medicine.
HopeLLM, is a revolutionary time saver that may be used by clinicians across City of Hope's national clinical network, enabling patients to receive world-class cancer care regardless of which City of Hope location they visit. In 2024 alone, City of Hope onboarded more than 150,000 patients. Doctors often see new patients with extensive medical histories spanning 10 to 20 years of test results, notes and treatment reports. Doctors need to spend significant time — often during nonworking hours — to review hundreds of pages, leading to less time interacting directly with patients.
Additionally, HopeLLM instantly points out a patient's clinical trial eligibility and automatically extracts key data points into research-ready formats, converting hours of manual chart review into seconds of AI-driven insight.
'We're not just building point solutions; we have built the engine for a learning health system where every patient interaction accelerates the next breakthrough,' says Nasim Eftekhari, M.S., City of Hope chief AI and analytics officer and system vice president.
Since 2017, City of Hope has been developing, deploying and optimizing life-saving AI-driven predictive models that are actively integrated into clinical workflows. These AI models help identify critical risks — such as sepsis in vulnerable populations and complications in surgical procedures — enabling timely clinical interventions that enhance patient outcomes and improve patient quality of life. Importantly, these predictive models provide risk scores along with contextual explanations that clarify the factors driving the prediction, empowering responsible AI-driven clinical decision-making support.
City of Hope's pioneering AI initiatives extend to oncology drug discovery, early cancer detection and prevention, advanced diagnostics and deeper insights into cancer evolution and disease progression. As an organization that both develops and uses AI tools, City of Hope is committed to harnessing artificial intelligence to enhance patient care, advance research and improve health care efficiency.
HopeLLM exemplifies City of Hope's AI work, where people with cancer benefit directly. For example, patients and doctors typically share the burden of providing and verifying medical history. However, HopeLLM shifts this responsibility away from patients, helping them to receive more personalized care and engage in focused, future-looking discussions with their doctors. HopeLLM allows patients to concentrate on their primary responsibility: recovery.
To receive a second opinion at City of Hope Los Angeles, call 888-720-1621 or visit this webpage.
About City of Hope
City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the United States, and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked a Top 5 'Best Hospital' in the nation for cancer care by U.S. News & World Report at its core, City of Hope's uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope's growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope's affiliated group of organizations includes Translational Genomics Research Institute and AccessHope TM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
TME Pharma Appoints Diede van den Ouden as New CEO at the 2025 Annual General Meeting of Shareholders
BERLIN, June 25, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the unanimous approval of all resolutions submitted to its 2025 annual general meeting of shareholders (AGM), including the appointment of Diede van den Ouden as sole member of the board of directors and Chief Executive Officer as a successor to Aram Mangasarian. The shareholders representing 16.67% of the total issued and outstanding share capital on May 28, 2025, were represented at the AGM which took place on June 25, 2025, at 03:00 p.m. CEST. "On behalf of the Board and the entire TME Pharma team I would like to welcome Diede van den Ouden as our new CEO. Diede's commitment to TME Pharma, demonstrated both as a significant shareholder and an active supporter, gives us great confidence as we enter this next chapter," said Maurizio PetitBon, Chairman of TME Pharma. "I would also like to extend our heartfelt thanks to Aram for his invaluable leadership over the past years during which TME Pharma achieved tremendous advances, especially with regard to the industry-leading clinical data generated in glioblastoma – one of the most challenging areas in oncology. We wish Aram the very best in his next venture and are pleased that he will stay involved with the TME R&D programs on an advisory basis. The Supervisory Board looks forward to working with Diede to continue driving our strategic objectives, including securing funding and partnerships for NOX-A12 and NOX-E36." "I am honored to join TME Pharma at such a pivotal moment in the company's journey. Thanks to the dedication and vision of the entire team, TME Pharma has reached a critical inflection point, marked by robust clinical progress and a strengthened financial position, with reduced cash burn and a secured 12-month runway," said Diede van den Ouden, the newly elected CEO of TME Pharma. "Building on this solid foundation, my focus will be on leading the company through its next phase of transformation, accelerating our strategic initiatives for both NOX-A12 and NOX-E36. As a major shareholder myself, my interests are fully aligned with those of our shareholders, and I am committed to delivering long-term value for all stakeholders." The full list of resolutions can be found below. Item Resolution 2.c. Adoption of the annual accounts 2024 Accepted 2.d. Release from liability of the sole member of the board of directors Accepted 2.e. Release from liability of the members of the supervisory board Accepted 3. Appointment of Diede Mink van den Ouden as sole member of the board of directors Accepted 4. Re-appointment of Susan Coles as member of the supervisory board Accepted 5. Amendment of the remuneration policy regarding the compensation structure of managing and supervisory board directors Accepted 6. Appointment of Baker Tilly (Netherlands) B.V. as statutory auditor for the financial year 2025 Accepted 7. Partial amendment of the articles of association in relation to the increase of the authorized share capital Accepted 8. Partial amendment of the articles of association in relation to re-instating a transitional provision to further increase the authorized share capital Accepted 9. Renewal of the delegation to the board of directors to issue ordinary shares and/or preference shares and to limit or exclude any pre-emptive rights in connection therewith Accepted 10. Renewal of the delegation to the board of directors to acquire shares Accepted The presentation outlining the agenda items and voting results of the AGM is available online. The minutes of the AGM will soon be made available on the company website. About TME Pharma TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, TME Pharma's approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA Phase 1/2 clinical trial, TME Pharma is studying its lead drug candidate NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer) in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses, and improved survival. US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma and TME Pharma was awarded fast track designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. TME Pharma has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in the United States. The company's second clinical-stage drug candidate, NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), showing potential to address fibrosis and inflammation is evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect. Further information can be found at: TME Pharma® and the TME Pharma logo are registered trademarks. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp. Visit TME Pharma on LinkedIn and X. About the GLORIA Study GLORIA (NCT04121455) is TME Pharma's dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy and bevacizumab. About the OPTIMUS Study OPTIMUS (NCT04901741) is TME Pharma's planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients. Disclaimer Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements." Forward-looking statements are based on TME Pharma's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma's ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law. View source version on Contacts For more information, please contact: TME Pharma N.V. Diede van den Ouden, CEOTel. +49 (0) 30 16637082 0ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
DaysToHappy Unveils Happy 2.0: Scalable Mental Health Support for the Modern Workplace and Campus
BOISE, Idaho--(BUSINESS WIRE)--DaysToHappy today announced the launch of Happy 2.0, a revolutionary mental health platform designed to help HR leaders and university administrators address rising rates of depression and anxiety among employees and students—at scale, and without overburdening traditional mental health systems. 'We're all about results—improving mental health by twenty percent in three weeks.' Built for today's fast-moving organizations and campuses, Happy 2.0 combines AI-driven mental health training, live group coaching, support communities, and ongoing assessments to provide immediate, around-the-clock mental health support—without the delays or limitations of therapist availability. 'We've built Happy 2.0 to solve what HR and campus wellness leaders have struggled with for years—how to deliver meaningful, measurable mental health support to thousands, instantly,' said Corey Davis, Founder of DaysToHappy. 'We're all about results—improving mental health by twenty percent in three weeks.' Key Benefits for HR and University Leaders: No App. No Login. No Integration Required. Launch to thousands of users in seconds, with zero tech lift. Available 24/7 Always-on access to coaching and community support, beyond office or counseling center hours. Scales with Your Organization Whether you're supporting 500 employees or 40,000 students, Happy 2.0 adapts instantly to meet demand. Drives Measurable Behavior Change Built-in assessments and tracking help HR and wellness teams see improvements over time, from engagement to emotional resilience. 'We all grew up with PE—Physical Education. But the world has changed. Now is the time for ME—Mental Education,' said Corey Davis. 'Happy 2.0 empowers organizations and institutions to support mental well-being proactively and at scale.' Why It Matters Now Traditional mental health solutions rely on therapists whose availability is limited—and often inaccessible during key moments of stress. Happy 2.0 changes the model, offering instant, scalable support that complements (not replaces) clinical care by meeting users where they are, when they need it. Whether you're leading a workforce or a student body, Happy 2.0 makes it possible to provide whole-person support that's always on, always human, and always impactful. About DaysToHappy, Inc. DaysToHappy is a behavior technology company transforming the way people experience mental health support. Through innovative tools that blend AI, interactive learning, live coaching, and community, DaysToHappy improves emotional well-being without the constraints of therapy-based systems.
Yahoo
an hour ago
- Yahoo
Mandolin Raises $40M to Improve Access to Life-Saving Therapies for Diseases like Cancer and Alzheimer's Using AI Agents
Mandolin brings AI teammates to healthcare, accelerating patient access and cutting operational cost SAN FRANCISCO, June 25, 2025--(BUSINESS WIRE)--Mandolin, the leading AI automation platform for specialty drug access, announced that it has raised $40 million in funding from Greylock Partners, SignalFire, Maverick, SV Angel, along with Jerry Yang (co-founder of Yahoo!) and Guillermo Rauch (CEO of Vercel). Founded by repeat entrepreneurs Will Yin (CEO) and Rohit Rustagi (COO), Mandolin is used by many of the nation's largest infusion providers, pharmacies, and health systems. Recent advances in drug development have caused an explosion of specialty therapies addressing rare and chronic conditions like cancers, immune disorders, and Alzheimer's. Specialty therapies represented $250 billion in drug spend in 2024 and are expected to reach $1.5 trillion in drug spend in eight years. They are also 75% of the drugs in the FDA's approval pipeline. Unlike traditional drugs bought at retail pharmacies, these drugs are often administered by healthcare professionals in a clinical setting. They are also processed through an arduous administrative process established by insurance companies, often delaying patients' access to life-changing treatments by weeks. "Insurance companies make the approval process challenging for specialty medications. Infusion providers, pharmacies, and health systems spend an excessive amount of manpower on basic tasks like checking insurance coverage, submitting prior authorizations, or verifying reimbursement amounts, which take weeks of time per prescription and lead to millions in bad debt," said Will Yin, CEO and co-founder of Mandolin. "Leveraging the latest advancements in AI, we saw an opportunity to build autonomous agents that can tackle these workflows for providers in minutes and more reliably." Mandolin's founders, Will Yin and Rohit Rustagi, have a strong passion and vision for improving our healthcare system using AI. After initially pursuing academic research on conditions like Alzheimer's and cancer that have impacted their families, they saw first-hand the difficulty and delays associated with specialty drug approvals. Recognizing how broken the healthcare system was for accessing these treatments, combined with the insight that large language models could now reason like the best performing employees, they joined forces to start Mandolin in 2024. Mandolin's AI platform automates the end-to-end administrative side of infused and injected drug delivery for providers. Mandolin's AI agents act just like your best employees, completing tasks like reasoning about clinical policies, calling payers, parsing faxes and handwritten notes, and making decisions across entire workflows. They integrate into existing electronic health records (EHRs), payer portals, and manufacturer hubs. By centralizing operational logic and real-time decision-making into a single platform, Mandolin dramatically reduces time-to-treatment from weeks to days, lowers back-office costs, improves billing accuracy, and unlocks visibility into drug usage and patient pathways. Since launching its product in January, the industry has been quick to respond. Mandolin is already working with many of the largest US infusion providers, pharmacies, and health systems, including Vivo Infusion, FlexCare Infusion, OI Infusion, TwelveStone Health Partners, and Amber Specialty Pharmacy. Across customers, Mandolin is deployed in over 700 clinic locations and serves over 250,000 new patients a year. "Mandolin has been nothing short of transformational for our business. Tasks that used to take days, now happen in under an hour," said Cannon Loughry, COO of TwelveStone. "We've automated key workflows across billing, patient communication, and insurance verification, driving real gains in terms of better cash flow and the reduction of headcount as we scale. Mandolin acts as an AI employee integrated directly into our core systems. We just tell it what needs to get done, and it does the work." "Will and Rohit saw the opportunity to bring agentic AI into a system drowning in paperwork, delays, and revenue leakage," said Jerry Chen, partner at Greylock Partners. "Despite being founded a year ago, Mandolin is already proving that AI agents can unlock faster treatment for patients and far better economics for providers. We at Greylock are thrilled to partner with them on their journey." About Mandolin Mandolin is the leading AI automation platform for specialty drug access. The company's AI agents act just like a best employee, completing tasks like reasoning about clinical policies, calling payers, parsing faxes and handwritten notes, and making decisions across entire workflows. Backed by Greylock, SignalFire, Maverick, and SV Angel, Mandolin works with the largest consolidated infusion providers, specialty and home infusion pharmacies, and health systems in the country. For more information, visit: View source version on Contacts Media Contact: Mandolin PR — press@
